Graig Suvannavejh Analyst Performance

Managing Director, Senior biopharmaceuticals and biotechnology equity research analyst at Mizuho

Graig Suvannavejh is a stock analyst at Mizuho in the medical sector, covering 17 publicly traded companies. Over the past year, Graig Suvannavejh has issued 21 stock ratings, including buy and hold recommendations. While full access to Graig Suvannavejh's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Graig Suvannavejh's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Analyst Ranking

Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeat

Average Return

00.00% 12-Month ROI

Success Rate

00.00% Profitable Ratings

Total Ratings

33 Last 6 Years

Buy Recommendations

90.32% 28 Buy Ratings

Companies Covered

17 Unique Companies

Ratings Distribution

Rating	Percentage	Count
Strong Buy	0.0%	0 ratings
Buy	90.3%	28 ratings
Hold	9.7%	3 ratings
Sell	0.0%	0 ratings

Out of 31 total stock ratings issued by Graig Suvannavejh at Mizuho, the majority (90.3%) have been Buy recommendations, followed by 9.7% Hold.

Best & Worst Calls

• Best Call

  0000.0%

  BCYC

  Sep 2019

  Subscribe to MarketBeat All Access to get analyst recommendation ROI.
• Worst Call

  000.0%

  ALEC

  Jul 2021

  Subscribe to MarketBeat All Access to get analyst recommendation ROI.

Exchange Coverage

Exchange	Percentage	Count
NASDAQ	100.0% of companies on NASDAQ	17 companies

Graig Suvannavejh, an analyst at Mizuho, currently covers 17 companies listed on , with the majority traded on NASDAQ.

Coverage Focus

Sector Icon	Sector	Percentage
	Medical 17 companies	100.0%

Graig Suvannavejh of Mizuho specializes in stock coverage within the Medical sector.

Coverage Industries

Industry	Percentage
MED - BIOMED/GENE 15 companies	88.2%
MED - DRUGS 1 company	5.9%
PHARMACEUTICAL PREPARATIONS 1 company	5.9%

Graig Suvannavejh's Ratings History at Mizuho

Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 4 Years 5 Years All Time Timeframe

Start Date

End Date

All Ratings Strong Buy Buy Hold Sell Rating

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription

12-Month ROIUpgrade to All Access to use the All ROI Filter

Export to Excel

Company	Report Date	Action	Report Date Price	12-Month Price Target	Rating	12-Month Price & ROI	Details
IDYA IDEAYA Biosciences	9/12/2025	Boost Price Target	$25.12	$44.00	Outperform	$0.00 00.00% ROI
KALA KALA BIO	9/8/2025	Initiated Coverage	$14.55	$30.00	Outperform	$0.00 00.00% ROI
INSM Insmed	8/13/2025	Boost Price Target	$122.00	$165.00	Outperform	$0.00 00.00% ROI
ALEC Alector	7/28/2025	Upgrade	$1.76	$3.50	Outperform	$0.00 00.00% ROI
NMRA Neumora Therapeutics	7/16/2025	Boost Price Target	$1.45	$5.00	Outperform	$0.00 00.00% ROI
ADAP Adaptimmune Therapeutics	6/26/2025	Downgrade	$0.25	$0.50	Neutral	$0.00 00.00% ROI
ADVM Adverum Biotechnologies	6/26/2025	Lower Price Target	$2.47	$12.00	Outperform	$0.00 00.00% ROI
IMRX Immuneering	6/18/2025	Boost Price Target	$2.18	$10.00	Outperform	$0.00 00.00% ROI
INSM Insmed	6/11/2025	Boost Price Target	$98.09	$110.00	Outperform	$0.00 00.00% ROI
CRVS Corvus Pharmaceuticals	5/20/2025	Set Price Target	$3.57	$11.00	Outperform	$0.00 00.00% ROI
EYPT Eyepoint Pharmaceuticals	5/16/2025	Lower Price Target	$5.93	$26.00	Outperform	$0.00 00.00% ROI
HRMY Harmony Biosciences	5/15/2025	Boost Price Target	$33.87	$48.00	Outperform	$0.00 00.00% ROI
APLS Apellis Pharmaceuticals	5/14/2025	Lower Price Target	$16.86	$20.00	Neutral	$0.00 00.00% ROI
AMLX Amylyx Pharmaceuticals	4/7/2025	Upgrade	$3.43	$7.00	Outperform	$0.00 00.00% ROI
AXSM Axsome Therapeutics	3/27/2025	Boost Price Target	$119.16	$216.00	Outperform	$0.00 00.00% ROI
HRMY Harmony Biosciences	3/18/2025	Boost Price Target	$34.32	$44.00	Outperform	$0.00 00.00% ROI
AXSM Axsome Therapeutics	2/26/2025	Boost Price Target	$129.67	$212.00	Outperform	$0.00 00.00% ROI
ITCI Intra-Cellular Therapies	2/24/2025	Downgrade	$128.60	$132.00	Neutral	$0.00 00.00% ROI
HRMY Harmony Biosciences	2/20/2025	Lower Price Target	$34.92	$42.00	Outperform	$0.00 00.00% ROI
AXSM Axsome Therapeutics	2/11/2025	Boost Price Target	$127.08	$195.00	Outperform	$0.00 00.00% ROI
AXSM Axsome Therapeutics	2/3/2025	Boost Price Target	$107.14	$137.00	Outperform	$0.00 00.00% ROI

Stock Forecasts and Research Tools

Sign in to your free account to enjoy these benefits

• In-depth profiles and analysis for 20,000 public companies.
• Real-time analyst ratings, insider transactions, earnings data, and more.
• Our daily ratings and market update email newsletter.

Sign in to your free account to enjoy all that MarketBeat has to offer.

• Sign In
• Create Account

Your Email Address:

Email Address Required

Your Password:

Password Required

Log In

---

or

Sign in with Facebook Sign in with Google

Forgot your password?

Your Email Address:

Please enter your email address.

Please enter a valid email address

Choose a Password:

Please enter your password.

Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character.

Create My Account (Free)

---

or

Sign in with Facebook Sign in with Google

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.